51. The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome.
- Author
-
Meyers NL and Hickling RI
- Subjects
- Action Potentials drug effects, Action Potentials physiology, Adolescent, Adult, Animals, Anti-Infective Agents pharmacology, Arrhythmias, Cardiac chemically induced, Aza Compounds pharmacology, Cell Line, Cisapride adverse effects, Cisapride pharmacology, Cisapride therapeutic use, Cross-Over Studies, Electrocardiography, Ether-A-Go-Go Potassium Channels antagonists & inhibitors, Ether-A-Go-Go Potassium Channels metabolism, Female, Fluoroquinolones, Gastrointestinal Agents adverse effects, Gastrointestinal Agents pharmacology, Gastrointestinal Agents therapeutic use, Heart drug effects, Heart physiology, Heart Rate drug effects, Humans, Male, Moxifloxacin, Placebos, Purkinje Fibers drug effects, Purkinje Fibers metabolism, Quinolines pharmacology, Serotonin Receptor Agonists adverse effects, Serotonin Receptor Agonists pharmacology, Serotonin Receptor Agonists therapeutic use, Sheep, Benzamides adverse effects, Benzamides pharmacology, Benzamides therapeutic use, Bridged Bicyclo Compounds, Heterocyclic adverse effects, Bridged Bicyclo Compounds, Heterocyclic pharmacology, Bridged Bicyclo Compounds, Heterocyclic therapeutic use, Irritable Bowel Syndrome drug therapy, Serotonin Antagonists adverse effects, Serotonin Antagonists pharmacology, Serotonin Antagonists therapeutic use
- Abstract
The cardiac safety of renzapride, a novel benzamide currently under clinical development for the treatment of irritable bowel syndrome, was investigated in a four-way randomized crossover electrocardiographic clinical study in healthy human subjects and also in an in vitro cardiac conductivity study in sheep isolated Purkinje fibres. The primary endpoint in the clinical study was prolongation of the individually corrected QT interval (QTci). No clinically or statistically significant prolongation of QTci after 4 or 20 mg renzapride compared with placebo was observed. The relative effects of renzapride and cisapride in the in vitro study showed that the cardiac action potential duration was unaltered by 0.2 and 2 microM renzapride, shortened by 20 microM renzapride, and prolonged by 1 microM cisapride. Cisparide was also a 1000-fold more potent inhibitor of human ether-a-go-go related gene (hERG) channels in HEK293 cells than renzapride. These studies indicate that therapeutic doses of renzapride are unlikely to prolong cardiac action potentials and, therefore, are also unlikely to cause cardiac arrhythmias in clinical use.
- Published
- 2007
- Full Text
- View/download PDF